Liudmila K Palgova

ORCID: 0000-0003-0973-1312
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Diet, Metabolism, and Disease
  • Liver Disease and Transplantation
  • Drug-Induced Hepatotoxicity and Protection
  • Alcohol Consumption and Health Effects
  • Trace Elements in Health
  • Microscopic Colitis
  • Chemotherapy-induced organ toxicity mitigation
  • Folate and B Vitamins Research
  • Drug Transport and Resistance Mechanisms
  • Celiac Disease Research and Management
  • Pharmacogenetics and Drug Metabolism
  • Inflammatory Bowel Disease

St Petersburg University
2017-2021

Saint Petersburg State Pediatric Medical University
2021

Objective The concept of using naturally occurring compounds such as polyenylphosphatidylcholine (PPC) an adjunctive therapy to treat non-alcoholic fatty liver disease (NAFLD) and alleviate or reverse hepatic steatosis appears a very attractive option for protection. We aim evaluate if PPC can effectively improve the ultrasonographic features NAFLD in routine clinical practice Russian patients with cardiometabolic comorbidities. Design This 24-week, observational, prospective study was...

10.1136/bmjgast-2019-000341 article EN cc-by-nc BMJ Open Gastroenterology 2020-01-01

Objective Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal results function tests. Earlier research showed that polyenylphosphatidylcholine (PPC) has hepatoprotective effects and thus can be used for treatment NAFLD prevention its progression. Accordingly, aim this observational study was to evaluate if PPC administered as adjunctive therapy in routine clinical practice effectively improve tests Russian patients with associated metabolic comorbidities. Design A...

10.1136/bmjgast-2019-000368 article EN cc-by-nc BMJ Open Gastroenterology 2020-03-01

Previous research conducted in Russia showed that the number of patients with non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large. We an observational study to describe management NAFLD syndrome Russia.A total 2843 adult from 174 medical sites across 6 federal districts newly diagnosed NAFLD, who had at least one four comorbidities, namely overweight/obesity, hypertension, type 2 diabetes mellitus, hypercholesterolaemia, received phosphatidylcholine...

10.1136/bmjgast-2019-000307 article EN cc-by-nc BMJ Open Gastroenterology 2019-08-01

While no "gold-standard" pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) is yet established, essential phospholipids (EPLs) are reported to decrease steatosis and improve laboratory parameters. This analysis evaluated adherence satisfaction with EPL treatment as patient-reported outcomes their relationship changes in ultrasound parameters among Russian patients NAFLD. Data were pooled from three observational studies—MANPOWER (2015–2016), LIDER 1 (2012–2013), 2 (2013)—in which...

10.1007/s40801-021-00250-x article EN cc-by-nc Drugs - Real World Outcomes 2021-05-15

ЭПИДЕМИОЛОГИЧЕСКИЕ ОСОБЕННОСТИ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ В СЕВЕРО-ЗАПАДНОМ РЕГИОНЕ РОССИИ (РЕЗУЛЬТАТЫ ОТКРЫТОГО МНОГОЦЕНТРОВОГО

10.21638/11701/spbu11.2017.201 article RU Vestnik of Saint Petersburg University Medicine 2017-01-01

The aim of the study was evaluation efficiency essential phospholipids for treatment drug-induced liver disease in pregnant women. In research group included 67 women with clinical and biochemical manifestations cytolytic syndrome, 58 (the main group) were treated hepatoprotectors, 9 control wasn’t carried out. Patients both groups eliminated hormonal drugs other or their dosage is reduced as much possible. Drug pregnancy manifested by increased transaminase, some cases accompanied level...

10.17816/jowd66214-23 article EN cc-by Journal of obstetrics and women s diseases 2017-03-15

This review includes information about epidemiological data, development feature, phenotypes, principles of classification, diagnosis, and prognosis for drug-induced liver injury (DILI). Actual clinical recommendations regarding management the DILI arising in chemotherapy cancer discussed. Drugs that can influence on individual pathogenetic mechanisms growth symptoms are considered. Clinical studies prophylaxis treatment associated with anticancer analyzed detail. The prevention regimens...

10.17650/1818-8346-2020-15-3-80-94 article EN cc-by Oncohematology 2020-10-16

Aim . To study characteristic features of nutritional status patients with Wilson ’s disease depending on stage liver damage and determine the impact malnutrition oxidative stress level. Methods The included 73 subjects, 33 (15 men 18 women) had a confi rmed diagnosis Wilson’s disease. All (the group) damage: non-cirrhotic stages — 12 (36.3%), cirrhosis 21 (63.6%). control group consisted 40 healthy subjects (20 20 neither body weight defi ciency, nor obesity, were conducted standard blood...

10.31146/1682-8658-ecg-176-4-39-45 article EN cc-by Experimental and Clinical Gastroenterology 2020-06-25

Aim . Estimation of the liver steatosis and fibrosis incidence with transient elastography controlled attenuation parameter in residents St. Petersburg. Materials methods A prospective open single-centre population study included history, anthropometric laboratory data on 318 outpatients aged 24—89 years (mean age 52.6 ± 14.6 years). The degrees (assessed as ultrasound amplitude dropdown quantification liver) were determined a Fibroscan 502 Touch unit (Echosens, France). Results Hepatic...

10.22416/1382-4376-2021-31-1-31-38 article EN cc-by-nc-nd Russian Journal of Gastroenterology Hepatology Coloproctology 2021-04-01
Coming Soon ...